In the CD5+ B cells subgroup, the proportion of CD5+ B cells in patients with CKD stages III–IV (8.37 [5.04–14.9]) and CKD stage V (8.89 [4.51–13.2]) was significantly lower compared to that of both healthy controls (19.6 [15.2–26.7]) and CKD stages I–II patients (19.0 [14.8–24.4]). This evidence concerns the gene CD5 and chronic kidney disease.